Clinical pharmacists' role in improving osteoporosis treatment rates among elderly patients with untreated atraumatic fractures

Annals of Pharmacotherapy

Volumn 42, Issue 3, 2008, Pages 334-340

  Nadrash, T Ann ^a   Plushner, Susyn Lynn ^b   Delate, Thomas ^a  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Atraumatic fracture; Osteoporosis; Pharmacist intervention

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; PAMIDRONIC ACID; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AGED; AMBULATORY CARE; ARTICLE; BONE DENSITY; CLINICAL PHARMACY; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG INDICATION; FEMALE; GERIATRIC PATIENT; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHARMACIST; PHARMACIST ATTITUDE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PHARMACISTS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 41149154912     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K541     Document Type: Article

References (19)

1. Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 2003;23:190-8.
2. Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J. Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int 2003;14:780-4.
3. Gelbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000;11:577-82.
4. Simonelli C. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334-8.
5. Neuner JM, Zimmer JK, Hamel MB. Diagnosis and treatment of osteoporosis in patients with vertebral compression fractures. J Am Geriatr Soc 2003;51:483-91.
6. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 2001;286:2815-22.
7. Togerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998;57:378-9.
8. Smith MD, Ross W, Ahern MJ. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip and wrist fractures. J Rheumatol 2001;28:2504-8.
9. Feldstein A, Elmer P, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003;163:2165-72.
10. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-7.
11. Hawker G. The impact of a simple fracture clinic intervention in improving the diagnosis and treatment of osteoporosis in fragility fracture patients. Osteoporos Int 2003;14:171-8.
12. National Committee for Quality Assurance. HEDIS 2004. Vol 2. Technical specifications update. October 1, 2003. web.ncqa.org/Portals/0/HEDISQM/Archives/ 2004/HEDIS04Update_Final.pdf. (accessed 2003 Sept 22).
13. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Ann Arbor, MI: National Center for Health Statistics, 1737-2167.
14. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
15. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, April 2003.
16. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
17. WHO Study Group Report. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1994;243:1-129.
18. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing fractures. Lancet 1996;348:1535-41.
19. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.